Erasca rises on trial and supply collaboration with Novartis
14/02/2024 17:00
** Cancer drug developer Erasca's ERAS.O shares rise 3.3%
to $1.72
** Co announces new collaboration and supply agreements with
Novartis NOVN.S
** The agreements will support an early-stage and late-stage
trials testing ERAS' experimental drug naporafenib in
combination with NOVN's approved drug Mekinist
** Co is sponsoring the trials and NOVN is supplying
Mekinist at no cost
** ERAS expects to report results from last-stage study in
H1-24 and between Q2 and Q4 2024 from early-stage study
** Stock down 57.2% in last 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))